Evidence map›Paper›PMID 32214474›Full record

ReviewMolecular biology2015

Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents.

O I Kiselev, A V Vasin, M P Shevyryova, E G Deeva, K V Sivak, V V Egorov, V B Tsvetkov, A Yu Egorov, E A Romanovskaya-Romanko, L A Stepanova and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

O I Kiselev1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
A V Vasin1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
M P Shevyryova3Ministry of Health of the Russian Federation, Moscow, 127994 Russia.
E G Deeva1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
K V Sivak1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
V V Egorov1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
V B Tsvetkov1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
A Yu Egorov1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
E A Romanovskaya-Romanko1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
L A Stepanova1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
A B Komissarov1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
L M Tsybalova1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.
G M Ignatjev1Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ebola hemorrhagic fever (EHF) epidemic currently ongoing in West Africa is not the first among numerous epidemics in the continent. Yet it seems to be the worst EHF epidemic outbreak caused by Ebola virus Zaire since 1976 as regards its extremely large scale and rapid spread in the population. Experiments to study the agent have continued for more than 20 years. The EHF virus has a relatively simple genome with seven genes and additional reading frame resulting from RNA editing. While being of a relatively low genetic capacity, the virus can be ranked as a standard for pathogenicity with the ability to evade the host immune response in uttermost perfection. The EHF virus has similarities with retroviruses, but belongs to (-)RNA viruses of a nonretroviral origin. Genetic elements of the virus, NIRV, were detected in animal and human genomes. EHF virus glycoprotein (GP) is a class I fusion protein and shows more similarities than distinctions in tertiary structure with SIV and HIV gp41 proteins and even influenza virus hemagglutinin. EHF is an unusual infectious disease, and studying the molecular basis of its pathogenesis may contribute to new findings in therapy of severe conditions leading to a fatal outcome.

Indexed as

antiviral drugsEbola virusgenomehemorrhagic feverinterferon antagonistsvaccines

Identifiers

PMID32214474
PMCPMC7089462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.